On Thursday, a team from Eli Lilly will take the hot seats in front of an advisory committee meeting of external FDA experts to make a case for necitumumab, another cancer drug which offers only marginal efficacy for advanced patients with a troubling profile for potentially lethal adverse events. And their odds-on chance of succeeding helps explain why this field has become so popular with drug developers.
Multinational drug firms in Australia faced a string of barbs in hearings held by a Senate panel into transfer pricing that included a reference to a fictitious German World War II prison camp guard.
Immunocore has added another string to its collaboration with Eli Lilly. The deal is intended to show whether there is value in combining Immunocore's lead T cell receptor-based therapy with galunisertib and merestinib in patients with metastatic cutaneous and uveal melanomas.
Shares in Adocia rose 10% after its Eli Lilly-partnered fast-acting insulin impressed in a small early-phase study. The data position Adocia to push ahead with development of a product that could surpass Lilly's blockbuster fast-acting insulin Humalog in terms of speed and effectiveness.
A U.S. judge refused to toss out lawsuits claiming that Eli Lilly & Co. downplayed withdrawal symptoms associated with its blockbuster antidepressant Cymbalta. As Bloomberg reports, Lilly will now have to fight claims that it misled consumers about "brain zaps" and other side effects suffered by people trying to quit using the drug.
Eli Lilly scored a victory in its patent battle for lung cancer blockbuster Alimta in Europe, as the Court of Appeal in London ruled against Actavis' plan to market copycat versions of the med.
The mayor of London has come up with a scheme to bridge the financial chasm between the U.K. and U.S. biotech hubs. Officials have called Eli Lilly, Pfizer and JP Morgan to a meeting to discuss the plan, which entails creating a £10 billion ($15 billion) fund to invest in drugs across the development spectrum, The Financial Times reports.
Eli Lilly and Teva, racing with a pack of drugmakers with a new approach to treating migraines, said their respective injected therapies succeeded in midstage trials, setting the stage for pivotal studies.
Novartis has had a complicated year: Three months ago, the Swiss drugmaker closed its multipart asset swap with GlaxoSmithKline, sending most of its troubled vaccines business to GSK and taking on the U.K. drugmaker's oncology business.
Eli Lilly inked a pair of deals with Harvard's Dana-Farber Cancer Institute and the Sarah Cannon Research Institute to hit the gas on oncology R&D, aiming to shorten the development process for a slew of new medicines.